139 related articles for article (PubMed ID: 37043830)
1. High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold.
Castera L; Laouenan C; Vallet-Pichard A; Vidal-Trécan T; Manchon P; Paradis V; Roulot D; Gault N; Boitard C; Terris B; Bihan H; Julla JB; Radu A; Poynard T; Brzustowsky A; Larger E; Czernichow S; Pol S; Bedossa P; Valla D; Gautier JF;
Diabetes Care; 2023 Jul; 46(7):1354-1362. PubMed ID: 37043830
[TBL] [Abstract][Full Text] [Related]
2. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
3. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
[TBL] [Abstract][Full Text] [Related]
4. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
[TBL] [Abstract][Full Text] [Related]
7. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.
Vieira Barbosa J; Lai M
Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
12. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
[TBL] [Abstract][Full Text] [Related]
13. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
16. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
[TBL] [Abstract][Full Text] [Related]
17. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
18. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
Poynard T; Deckmyn O; Peta V; Paradis V; Gautier JF; Brzustowski A; Bedossa P; Castera L; Pol S; Valla D;
Aliment Pharmacol Ther; 2023 Nov; 58(9):888-902. PubMed ID: 37642160
[TBL] [Abstract][Full Text] [Related]
19. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
